Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-escalation, Open-label, Non-randomized Phase I Study to Evaluate the Safety and Immunogenicity of Three Concentrations of a rNDV Vaccine Against SARS-CoV-2 Administered by the Intranasal and Intramuscular Route to Healthy Volunteers

NCT04871737 is registered in ClinicalTrials.gov with Laboratorio Avi-Mex, S.A. de C.V. as lead sponsor.

NCT NCT04871737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04871737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-escalation, Open-label, Non-randomized Phase I Study to Evaluate the Safety and Immunogenicity of Three Concentrations of a rNDV Vaccine Against SARS-CoV-2 Administered by the Intranasal and Intramuscular Route to Healthy Volunteers
Lead sponsor
Laboratorio Avi-Mex, S.A. de C.V.
Phase
Phase 1
Overall status
Completed
Start date
May 20, 2021
Completion date
September 30, 2022
Enrollment
91 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection